Form 4: Revance Therapeutics Director Julian S. Gangolli Reports Stock and Option Awards

Director Julian S. Gangolli reports acquisition of Revance Therapeutics stock and options as part of annual compensation.

Summary

• On May 1, 2024, Julian S. Gangolli, a director of Revance Therapeutics, Inc., acquired 15,000 shares of common stock and options to purchase 23,458 shares of common stock.
• The stock was granted as a restricted stock award (RSA) under the company's Amended and Restated Non-Employee Director Compensation Policy.
• The options were also granted under the same compensation policy.
• Both the RSA and the stock options vest on the earlier of May 1, 2025, or the day before the next annual stockholder meeting, contingent upon continued service as a director.
• The exercise price of the stock options is $3.795.
• Following these transactions, Gangolli beneficially owns 45,106 shares of common stock and options for 23,458 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard director compensation practices, aligning interests with shareholders. There are no indications of negative performance or concerns.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Director compensation in the form of stock and options is a common practice in the biotechnology industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Granting stock options and restricted stock to directors is a standard practice among publicly traded companies, particularly in the biotech sector.
• Companies like Allergan (now AbbVie) and Evolus also utilize equity-based compensation for their board members.
• The vesting schedules and amounts granted are generally benchmarked against peer companies to ensure competitiveness and alignment with performance.

Stakeholder Impact

• The granting of stock and options to a director can positively impact shareholders by aligning management's interests with theirs.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Revance Therapeutics, Director Compensation, Stock Options, Restricted Stock Award, Beneficial Ownership, Form 4, RVNC, Gangolli